Chad J. Wasserman - 18 Mar 2024 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
18 Mar 2024
Net transactions value
-$588,077
Form type
4
Filing time
20 Mar 2024, 17:16:04 UTC
Previous filing
21 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Options Exercise $212,436 +2,100 +109% $101.16 4,020 18 Mar 2024 Direct F1
transaction HCA Common Stock Tax liability $400,456 -1,224 -30% $327.17 2,796 18 Mar 2024 Direct F1
transaction HCA Common Stock Sale $110,758 -344 -12% $321.97 2,452 18 Mar 2024 Direct F1
transaction HCA Common Stock Sale $289,299 -876 -36% $330.25 1,576 20 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -2,100 -33% $0.000000 4,190 18 Mar 2024 Common Stock 2,100 $101.16 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercise of stock appreciation rights and sales of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2023.
F2 The stock appreciation rights vested in four equal annual installments beginning on January 31, 2019.